Galatea Bio, a Miami-based biotech company focused on advancing precision medicine and genomic research, has raised $25 million to build the world’s largest biobank to accelerate drug discovery in diverse populations.
The round of funding came from F-Prime, Helios Digital Ventures, Digitalis Ventures, AME Cloud, CEI Ventures, Alexandria, Founders Collective, Stanford President’s Fund, and HBM Genomics.
The company, founded in 2021, is expanding its Biobank of the Americas into the Galatea Global Biobank, aimed at sequencing 10 million participants worldwide. The funding will support the expansion of sequencing, AI-powered genomic analysis, and industry partnerships to refine genetic risk analysis for complex diseases.
“Galatea Bio envisions a future where healthcare is accessible to all and tailored to each individual’s genetic makeup and predicted future disease trajectory,” said Galatea Bio’s CEO and president, a population geneticist and Stanford faculty member. “By analyzing a broad spectrum of genetic, longitudinal health records, and real-world evidence data from multi-ancestry populations, Galatea is generating new insights into the biological processes that underlie health and disease – a process we are committed to accelerating. This work represents a critical step toward truly personalized healthcare on a global scale.”
With a laboratory in Miami Lakes, Galatea Bio provides full-service sequencing, molecular diagnostics and AI-enhanced genomic analysis. The company’s primary focus is to overcome the limitations of current genomic research, which predominantly relies on data from individuals of European descent. Galatea Bio aims to address this gap by sequencing 10 million participants worldwide, with an emphasis on people of non-European ancestry. Its efforts are all designed to enhance predictive disease models and accelerate personalized healthcare, the company said.
“Galatea Bio is already a well-established leader in genomics, with a strong foundation of collaborations driving innovation in research and personalized medicine,” said F-Prime Venture Partner Muzammil Mansuri. “Their approach unlocks the full potential of genetic data at scale, transforming how we understand and apply genomics to human health.”
The biobank will integrate data from various sources, including clinical health records and real-world evidence, to offer a more comprehensive and accurate reference population for scientific research, creating innovative platforms that refine genetic risk analyses, accelerate drug discovery, and optimize clinical trials.
“Africa holds the richest tapestry of human genetic variation on Earth yet remains mostly absent in global genomics research. This gap not only limits our understanding of human biology but obscures pathways to medical breakthroughs that could benefit humanity globally,” said Wale Ayeni, Managing Partner at Helios Digital Ventures. “Galatea Bio is uniquely positioned to illuminate these intricate genetic patterns using AI and multi-omics integration, creating a new paradigm that could transform precision medicine worldwide.”
Galatea Bio has built strategic partnerships with health systems and institutions such as the Chan Zuckerberg Initiative, which is also funding cancer research at the University of Miami. Galatea Bio is also collaborating with Baptist Health in South Florida.
To further bolster its leadership team, Galatea Bio recently appointed Jeff Gulcher as Chief Medical Officer and Francisco M. De La Vega as Chief Technology Officer. Mansuri and Ayeni are joining the board.
READ MORE IN REFRESH MIAMI’
- WunderGraph raises $7.5M to scale its open source API platform with help from eBay
- Miami metro’s startups raised $2.77B in 2024, ranking South Florida as a top 10 VC hub, eMerge Insights finds
- Crossmint raises $23.6M to bring businesses and AI commerce onchain
- MDC’s new Build Up program aims to power Miami’s next wave of entrepreneurs - February 9, 2026
- beHuman raises $4M seed round to expand AI-driven early cancer detection - February 4, 2026
- SynthBee raises a fresh $80M in funding from Crosspoint Capital Partners - February 4, 2026